Prescribing Highlights for Common Drugs in Primary Care 0.97 CE / 0.97 RX This presentation will discuss some of the most commonly prescribed drugs in primary care. This session will highlight important drug considerations that are valuable to the busy clinician, such as FDA-approved indications, safety considerations, and evidence-based prescribing pearls. Objectives:- List one evidence based prescribing pearl for a commonly prescribed drug.
- List one contraindication or caution for a commonly prescribed drug.
- List one potential adverse effect for a commonly prescribed drug.
Updates in Pharmacology and Prescribing for the Acute Care Nurse Practitioner (Part 1) 1.25 CE / 0.63 RX Nurse practitioners practicing in acute and critical care environments frequently encounter adult patients with complex diagnoses that require a rapid and strategic approach to pharmacological prescribing. The purpose of this two-part session is to provide nurse practitioners working in hospital settings with current standards of practice and updates in evidence-based prescribing guidelines. This presentation will focus on common diagnoses and issues in acute care environments and provide practical resources on navigating the challenges associated with evaluating and managing acutely ill patients. Objectives:- Identify guideline directed medical therapies and diuretic strategies for acute heart failure.
- Recognize the medications used for rate control and thromboembolic prophylaxis in patients with atrial fibrillation.
- Describe evidence-based indications and dosages for thromboembolic and stress ulcer prophylaxis.
Updates in Pharmacology and Prescribing for the Acute Care Nurse Practitioner (Part 2) 1.10 CE / 0.83 RX Nurse practitioners practicing in acute and critical care environments frequently encounter adult patients with complex diagnoses that require a rapid and strategic approach to pharmacological prescribing. The purpose of this two-part session is to provide nurse practitioners working in hospital settings with current standards of practice and updates in evidence-based prescribing guidelines. This presentation will focus on common diagnoses and issues in acute care environments and provide practical resources on navigating the challenges associated with evaluating and managing acutely ill patients. Objectives:- Identify the pathophysiology and risk factors associated with inpatient opioid toxicity, acute hyperkalemia, and anaphylaxis.
- Evaluate the current evidence that supports medication selection, dosing, and monitoring.
- Appraise the strategies that can reduce medication side-effects and adverse outcomes.
Pharmacotherapy for Obesity: Now and the Future 1.15 CE / 1.15 RX The presentation will use case-based format to explain the use of current FDA approved anti-obesity medications. The future for AOM's will be reviewed. Objectives:- Recognize the role of pharmacotherapy in obesity treatment.
- Identify available pharmacotherapeutics that can be utilized to support treatment of chronic disease of obesity that are not labeled for obesity by the FDA.
- Apply the knowledge of obesity pharmacotherapeutics in a case study.
- Categorize therapeutics in the pipeline for obesity treatment.
Anti-Obesity Medications: Inside and Outside the Label 1.00 CE / 1.00 RX Anti-obesity medications can be expensive and may not be covered by insurance. This presentation will review the medications currently approved by the FDA and the literature on the use of off-label for the treatment of pre-obesity and obesity. Objectives:- Recognize the role of pharmacotherapy in obesity treatment.
- Evaluate FDA approved medications for the pharmacologic management of chronic disease of obesity.
- Identify available pharmacotherapeutics that can be utilized to support treatment of chronic disease of obesity that are not labeled for obesity by the FDA.
Immunization Update 2023: What's New in Vaccines 1.05 CE / 0.85 RX Vaccines are one of the best preventive measures for reducing vaccine-preventable diseases and cancers. This session will provide the NP with an understanding of how vaccines provide protection. In addition, we will discuss the most current vaccine recommendations across the lifespan, prevention of missed opportunities and increasing the vaccine rates in your practice, and current vaccines that are under development. Objectives:- Provide the latest information on vaccine recommendations for all age groups.
- Describe the mechanism of action of each vaccine type in providing an immune response.
- List five strategies for improving vaccine acceptance in your practice.
- Explain the difference between efficacy and effectiveness.
- Name several advances in vaccine technology and implications for future vaccines.
Antipsychotic Pharmacology and Use in Primary Care 0.75 CE / 0.75 RX According to data from the CDC, at least half of all Americans will experience a mental health problem in their lifetime. At any given time 1 in 5 people are experiencing symptoms that lead to a psychiatric diagnosis. With recent world events and the global pandemic these numbers have risen. Mental health complaints are often the chief complaint in primary care offices. This evidence-based presentation will provide an update on medications used to treat common mental health conditions, especially as it relates to those in a primary care role, particularly family and adult/gerontological nurse practitioners. The latest research and evidence-based prescribing guidelines related to psychopharmacology and the use of these medications in the primary care setting will be examined. The use of antidepressants, mood stabilizers and anti-psychotics will be explored and discussed. Risk/benefit prescribing as well as the appropriate monitoring of patients on these agents will also be examined and discussed. Objectives:- Identify indications for the use of antipsychotic medication.
- Discuss side effects of antipsychotic medication.
- Explore the atypical antipsychotics indicated in the treatment of mood disorders.
- Explain prescribing of atypical antipsychotic medication to patients with mood disorders.
- Discuss monitoring of patients on antipsychotic medication.
2023 Update on Pediatric Pharmacology 1.00 CE / 1.00 RX The FDA has averaged about 43 novel drug approvals per year for the past 10 years. In 2022, the U.S. Food and Drug Administration (FDA) approved 34 novel drugs and 12 new biological agents. Many of these new drugs are indicated for use in children. Additionally, more than 40 drugs including biologics, immunomodulators and HIV antivirals have been relabeled to be safe and effective in children and adolescents. This presentation will review newly approved or relabeled drugs for use in children and adolescents, and recent advances in pediatric pharmacology and prescribing knowledge. Issues that impact prescribing, such as Drug Safety or MedWatch alerts, and drug shortages, will be discussed. New and in-progress studies from the Pediatric Trials Network will be reviewed. Attendees will be able to incorporate information from this session immediately into their practice. Objectives:- Review new pediatric drugs on the market in 2022/2023.
- Discuss advances in pediatric prescribing knowledge.
- Discuss current issues impacting pediatric prescribing.
- Emerging medication or poisoning hazards.
- Discuss pediatric drugs on the horizon.
2023 Pediatric Immunization Update - Calling the Right Shots 1.10 CE / 0.94 RX Immunizations are prescribed by pediatric providers on a daily basis. Providers are tasked with keeping up to date on current immunization recommendations and evidence to provide care and educating parents about vaccines. This presentation will address current evidence regarding vaccine safety and efficacy in children and adolescents, including current guidelines for immunization practices. Tools for overcoming vaccine resistance will be presented, as well as resources providers can use in their practice. Objectives:- At the end of this session participants will have the most current information from the CDC regarding immunizations.
- At the end of this session participants will be familiar with the most current information regarding vaccine safety and efficacy.
- At the end of this session participants will be aware of vaccines in development.
The Right Drug for the Bug: Update on Pediatric Antibiotic Recommendations 1.13 CE / 1.13 RX Prescribing antibiotics happens daily in pediatric practice. This presentation will provide valuable updated information about prescribing antibiotics for children and adolescents. Antibiotic resistance will be discussed, including local and national resistance patterns and the use of antibiograms to guide prescribing. Current prescribing guidelines for common pediatric infections will be reviewed. Updated guidelines for pediatric community-acquired pneumonia in infants and children in development by the Infectious Disease Society of America will be presented, as well as potential updated pediatric otitis media and sinusitis guidelines. Current literature regarding shorted course of antibiotics for common pediatric infectious diseases will be discussed. Antibiotic stewardship principles that can be applied to practice will be explored, including the Agency for Healthcare Research and Quality (AHRQ) Safety Program 4 moments of antibiotic decision-making. Objectives:- Review of U.S. and global pediatric antibiotic resistance threats.
- Discuss progress toward national goals around antibiotic prescribing and reducing antibiotic resistance.
- Review current guidelines for prescribing for pediatric infectious diseases.
- Discuss decision-making about appropriate antibiotic choices.
Pharmacologic Management Considerations of Common Primary Care Conditions for People Living with HIV 1.00 CE / 1.00 RX People living with HIV (PLWH) and taking antiretroviral therapy (ART) may present to primary care providers for treatment of common conditions. This presentation will discuss important pharmacologic considerations when treating common primary care conditions in PLWH. The presenters will provide an overview of ART and discuss the potential for drug interactions involving ART and other prescribed drugs, over-the-counter products, herbal therapies and supplements. Potential clinical significance and adverse outcomes associated with these interactions will also be discussed. Evidence-based clinical resources to help NPs make safer prescribing decisions will be shared, as well as tips for use.) Objectives:- Describe the role of anti-retroviral therapy (ART) in the management of HIV.
- Identify two potential adverse effects of anti-retroviral therapy (ART).
- Use one based resource to check for drug-drug interactions.
- Identify one potential clinically significant drug interaction between anti-retroviral therapy (ART) and a common drug.
- Determine an appropriate action when there is a potential drug-drug interaction involving ART and a commonly prescribed drug.
Geriatric Pharmacology: What the NP Needs to Know 0.75 CE / 0.75 RX The population is aging. According to the U.S. Census Bureau, more than 56 million adults ages 65 and older live in the United States, accounting for about 16.9% of the nation's population. By 2030, when the last of the baby boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults. This session will review the pharmacodynamics, tools and considerations in prescribing for your older patients safely and effectively. Objectives:- Name five physiological changes of aging that could impact pharmacokinetics and pharmacodynamics in older adults.
- List the most recent changes to Beers criteria.
- State several adverse effects associated with anticholinergic drugs and list those drugs with the highest anticholinergic activity.
- Identify the components of a stepwise approach to prescribing.
|